CPT code 0120U denotes the Lymph3Cx Lymphoma Molecular Subtyping Assay, a Proprietary Laboratory Analyses (PLA) code for a Mayo Clinic laboratory-developed molecular test that sequences 58 genes from preserved biopsy tissue and integrates clinical data to evaluate the likelihood of primary mediastinal B–cell lymphoma (PMBCL) versus diffuse large B–cell lymphoma (DLBCL). This code captures a complex, high-specificity diagnostic service that informs lymphoma classification and downstream treatment decisions, making it nationally relevant as precision oncology testing expands.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise national overview of coverage and reimbursement context for this PLA molecular assay, clinical utility and indication context for PMBCL and DLBCL subtyping, typical billing and site-of-service considerations, and an outline of available benchmarks and policy updates where applicable. Data not available in the input is noted where gaps exist.

This publication is intended to inform coding, policy, and payer-facing stakeholders about the clinical intent and billing classification of CPT code 0120U, helping users understand where the assay fits within molecular diagnostics and oncology service lines at a national level.